Improved activity with irinotecan, oxaliplatin and infusional 5-FU/LV (FOLFOXIRI) compared with FOLFIRI in metastatic colorectal cancer (MCRC): results of a randomized Phase III trial by the Gruppo Oncologico Nord Ovest (GONO)

被引：0
|
作者：
Falcone, A.
Brunetti, I. M.
Benedetti, G.
Evangelista, W.
Picone, V.
Vitello, S.
Rosso, R.
Granetto, C.
Porcile, G.
Masi, G.
机构：
[1] Univ Study Pisa, Osped Civile, UO Oncol Med, Livorno, Italy
[2] Osped S Chiara, UO Oncol Med, Pisa, Italy
[3] Osped Bellaria, UO Oncol Med, Bologna, Italy
[4] Osped S Giovanni Molinette, COES, Turin, Italy
[5] Policlin Umberto 1, UO Oncol Med, Rome, Italy
[6] Osped S Elia, UO Oncol Med, Caltanissetta, Italy
[7] IST, Genoa, Italy
[8] Osped S Croce & Carle, SC Oncol Med, Cuneo, Italy
[9] Osped S Lazzaro, UO Oncol, Alba, Italy
[10] Osped Civile, UO Oncol Med, Livorno, Italy
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：167 / 168
页数：2
相关论文
共 50 条
  • [41] Prospective economic evaluation of phase III trial comparing irinotecan with infusional 5-FU in patients with advanced colorectal cancer
    Schmitt, C
    Jolain, B
    Van Cutsem, E
    MEDICAL DECISION MAKING, 1998, 18 (04) : 484 - 484
  • [42] Phase III trial of irinotecan plus oxaliplatin (IROX) versus irinotecan plus 5-FU/folinic acid (FOLFIRI) as first-line treatment of metastatic colorectal cancer (CRC): The FIRE-Trial.
    Schalhorn, A
    Ludwig, FW
    Quietzsch, D
    Maubach, PA
    Schlimok, G
    Lambertz, H
    Weigang-Koehler, K
    Schulze, M
    Schlag, R
    Grundeis, M
    Heinemann, V
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 250S - 250S
  • [43] Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC):: CALGB 80203 preliminary results.
    Venook, A.
    Niedzwiecki, D.
    Hollis, D.
    Sutherland, S.
    Goldberg, R.
    Alberts, S.
    Benson, A.
    Wade, J.
    Schilsky, R.
    Mayer, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 148S - 148S
  • [44] Irinotecan in second-line treatment of metastatic colorectal cancer: Improved survival and cost-effect compared with infusional 5-FU
    Iveson, TJ
    Hickish, T
    Schmitt, C
    Van Cutsem, E
    EUROPEAN JOURNAL OF CANCER, 1999, 35 (13) : 1796 - 1804
  • [45] Capecitabine (C) in combination with irinotecan (I) and oxaliplatin (O) (XELOXIRI) in patients with metastatic colorectal cancer (MCRC): Preliminary results of a pilot study by Gruppo Oncologico Nord-Ovest (G. O. N. O.)
    Bursi, Simona
    Masi, Gianluca
    Antonuzzo, Andrea
    Loupakis, Fotios
    Barbara, Cecilia
    Barletta, Maria
    Allegrini, Giacomo
    Pfanner, Elisabetta
    Murr, Rita
    Falcone, Alfredo
    ANNALS OF ONCOLOGY, 2006, 17 : 121 - 121
  • [46] Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial
    Van Cutsem, E.
    Nowacki, M.
    Lang, I.
    Cascinu, S.
    Shchepotin, I.
    Maurel, J.
    Rougier, P.
    Cunningham, D.
    Nippgen, J.
    Koehne, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Efficacy and safety findings from a randomized phase III study of capecitabine (X) plus oxaliplatin (O) (XELOX) vs. infusional 5-FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC)
    Ducreux, M.
    Bennouna, J.
    Hebbar, M.
    Ychou, M.
    Lledo, G.
    Conroy, T.
    Adenis, A.
    Faroux, R.
    Rebischung, C.
    Douillard, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] Phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI
    Sobrero, A. F.
    Young, S.
    Balcewicz, M.
    Chiarra, S.
    Perez Carrion, R.
    Mainwaring, P.
    Gapski, J.
    Clarke, S.
    Langer, B.
    Ackland, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] Final results of a randomized phase III trial comparing irinotecan plus oxaliplatin (IROX) to irinotecan monotherapy in patients with metastatic colorectal cancer (MCRC) previously treated with fluoropyrimidines
    Haller, Daniel G.
    Rothenberg, Mace L.
    Wong, Alfred O.
    Koralewski, Piotr M.
    Miller, Wilson H., Jr.
    Bodoky, Gyorgy
    Olivatto, Luis O.
    Burger, Brent G.
    Kearney, Jill G.
    Garay, Carlos A.
    ANNALS OF ONCOLOGY, 2004, 15 : 70 - 70
  • [50] INTRAVENOUS (IV) AFLIBERCEPT VERSUS PLACEBO IN COMBINATION WITH IRINOTECAN/5-FU (FOLFIRI) FOR SECOND-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC): RESULTS OF A MULTINATIONAL PHASE III TRIAL (EFC10262-VELOUR).
    Van Cutsem, Eric
    Tabernero, Josep
    Lakomy, Radek
    Prausova, Jana
    Ruff, Paul
    Van Hazel, Guy
    Moiseyenko, Vladimir
    Ferry, David
    McKendrick, Joe
    Tellier, Alexia
    Castan, Remi
    Allegra, Carmen
    ANNALS OF ONCOLOGY, 2011, 22 : v18 - v18
12345